Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Sanofi is buying U.K. biotechnology company Vicebio for up to $1.6 billion in a deal that seeks to strengthen the French drugmaker's portfolio of respiratory vaccines and leave pipeline setbacks ...

Investing.com - UBS initiated coverage on 3SBio Inc (HK: 1530) (OTC:TRSBF) with a Buy rating and a price target of HK$30.00 on Friday. The pharmaceutical company, which focuses on haematology and ...

Investing.com - UBS initiated coverage on 3SBio Inc (HK: 1530) (OTC:TRSBF) with a Buy rating and a price target of HK$30.00 on Friday.

Investing.com - UBS initiated coverage on 3SBio Inc (HK: 1530) (OTC:TRSBF) with a Buy rating and a price target of HK$30.00 on Friday. The pharmaceutical company, which focuses on haematology and ...

UBS views this record-making agreement as validation of 3SBio’s research and development capabilities, noting potential upside in SSGJ-707’s overseas peak sales and value from other pipeline ...

CoreWeave last year tried to acquire Core Scientific for $5.75 a share, which at the time valued the business at north of $1 billion. Core Scientific rejected the proposal as too low.

The segment was heavily boosted by the Seagen acquisition back in 2023, that has the potential to become a high-growth area for Pfizer.

A week after the Nippon-U.S. Steel deal was finalized, another Pittsburgh-based corporation announced it was set for an international acquisition. Moon-based water and wastewater treatment company ...

Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, the U.S. drugmaker said on Thursday.